Visit DOTmed at RSNA, North Hall B, Booth #6608 -- Ask about Clean Sweep Equipment Auctions

Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts


More Industry Headlines

Panel calls for radiologists to 'take a seat at the table' in shaping new payment model RSNA 2015

RSNA: Raising the bar on breast tomosynthesis The benefits of C-View software for improving the new standard in breast imaging

RSNA: FUJIFILM announces two major new DR innovations World's first long-length DR detector and FDR Visionary Suite

Philips launches IntelliSpace Portal 8.0 platform at RSNA More than 68 clinical applications for visualizing CT, MR, ultrasound, mammo, and more

New scattered X-ray method delivers a whole new view of your tooth Measuring structures as small as a billionth of a meter

Breast MR after mammography may catch additional aggressive cancers How clinically significant are multicentric cancers?

Will the future hold compact, tunable X-ray devices made of graphene? May reduce radiation dose and cost associated with current X-ray devices

Bilingual patients have better cognitive function after stroke But it may not apply to all bilingual people

Dell announces entry into health care monitor market New device is designed to meet IEC 60601-1 standard

Canadian hospital clerk who sold maternity records fined $27,000 — hospital facing $308.4 million suit From 1995 to 2014 she sold at least 14,450 records

Amyloid imaging lights up SNM 2012

by Loren Bonner , DOTmed News Online Editor
Presenters at the 59th annual SNM meeting in Miami Beach, Fla., unveiled an array of breakthrough research and new techniques to detect evidence of Alzheimer's in living patients -- including, possibly, in asymptomatic populations.

Researchers know that beta-amyloid plaque can build up in the brain several years before an individual shows any signs of dementia. And many scientists believe that this plaque can kill vital neural pathways that are responsible for language, memory and behavior.

Story Continues Below Advertisement

Innovating Health & Wellness Within Your World

Industry Leading Warranty and Service. Clinical safety and Ergonomics. Patient Safety and Comfort. Schedule a meeting with one of our sales professionals at 717-235-6807 to establish Oakworks as your table contract supplier.

"Molecular imaging can detect signs of Alzheimer's disease many years before patients develop dementia. It can do this because it can target beta-amyloid," says Dr. Christopher Rowe, a lead investigator for the Australian Imaging, Biomarkers and Lifestyle study of aging and professor of nuclear medicine at Austin Hospital in Melbourne, Australia.

In one of the studies presented by Rowe's team, PET was combined with an F-18 imaging agent. Subjects who showed high levels of the tracer during imaging had an 80 percent chance of developing Alzheimer's within two years, according to study findings.

Research also found that beta-amyloid plaque in the brain was not only involved in the pathology of Alzheimer's disease but also preceded mild cognitive function.

"For those with mild memory problems who had a positive scan, 66 percent of these people progressed to dementia over three years. This compares to only 7 percent of those with a negative scan," says Rowe.

Rowe highlighted findings on this study at the meeting, which included 194 healthy elderly subjects, 92 subjects with mild cognitive impairment, and 70 subjects with Alzheimer's. C-11 Pittsburgh compound B (PiB) combined with PET was used to gauge amyloid burden in the brain.

"This is an opportunity to find the patient who has Alzheimer's and intervene with treatments as they become available," says Rowe.

He pointed out that being able to correctly identify which patients have Alzheimer's and which don't is a necessary stepping stone for developing potential drugs and therapies to treat the disease.

Alzheimer's can only be detected in a patient after death-- by studying postmortem brain samples with beta-amyloid plaque.

Currently, no reliable treatment exists for Alzheimer's patients and the screening tests that do exist are unreliable and limited in their ability to identify the disease early.

New biomarkers emerge

Any PET amyloid imaging test must begin with a biomarker. This year's SNM meeting presented some promising amyloid imaging agents in development that will help clinicians detect Alzheimer's in living patients.

Continue reading Amyloid imaging lights up SNM 2012...
  Pages: 1 - 2 - 3 >>


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2015 DOTmed.com, Inc.